Helixgate https://validator.w3.org/feed/docs/rss2.html Home Beyond the Technology: AI Readiness in Regulated Laboratories STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans Vertex’s biggest overhang: a rival 50 times smaller Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine J&J pharma leader to retire; Krystal slumps on gene therapy miss As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger STAT+: Are AI scribes medical devices? UK regulator weighs in. Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure Latigo, BlossomHill detail IPO plans for pain and cancer push Trans federal employees sue over revoked health coverage NSF-Funded Test Bed Lets Researchers Program Automated Biomanufacturing Workflows Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab Vertex unfazed by competitive IgAN space as FDA verdict looms Genome Mapping Reveals Autoimmune Disease Risk Genes in Innate Lymphoid Cells STAT+: As Trump administration pushes court-ordered mental health care, a new report raises questions STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate case Combined Phage Therapy and FMT Reduces Recurrent UTIs and Antibiotic Use in First Human Case Series STAT+: After Eli Lilly granted one man special access to obesity drug, doctors struggle to get answers Michigan reports first two U.S. deaths in outbreak of cyclospora An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled. STAT+: Medicare eliminates key pathways used by ‘breakthrough’ devices for extra payments Evolutionarily Diverse Organisms Switch Genes on Simply and Switch Them off Dynamically Ractigen Therapeutics closes over $31 million financing  Supernus and Indivior merge to create CNS mega-company with 11 approved drugs Curium strikes up to $8B deal for radiopharma rival Lantheus Ancient Arctic carbon is pouring into the sea, but the seabed captures most of it STAT+: Is there a pharma mega-merger in the making? BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with states Novo’s late-stage IL-6 stumble shakes inflammation space STAT+: BioNTech names Guido Oelkers its new CEO ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever Receptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic Targets Heart transplants fail if patients get too weak. New program tries inpatient prehab  Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out 5 companies advancing ATTR assets in the wake of Wainua’s fail STAT+: Senate measure would block Trump plan to politicize federal grants, for now STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing De novo L-(+)-tartaric acid biosynthesis in multi-modular engineered yeasts StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel Rank-guided learning accelerates automated enzyme engineering Author Correction: Therapeutic application of circular RNA aptamers in a mouse model of psoriasis Capricor CEO won’t rule out legal action against FDA after negative adcomm Ketamine Triggers Sex-Specific Brain Recovery Responses STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitals Microbiota-Derived Metabolite Enhances HIV Therapy in Monkeys Lilly and Resilience invest $750M in diabetes and obesity drug device supply